Health knowledge and news provided by doctors.

International AIDS Vaccine Initiative statement on male circumcision

Armen Hareyan's picture

Circumcision and HIV

The International AIDS Vaccine Initiative (IAVI) issued this statement today following a National Institutes of Health (NIH) decision to end two clinical trials of adult male circumcision in Uganda and Kenya. The NIH's Data Safety and Monitoring Board (DSMB), reviewing interim data, found that medically performed circumcision significantly protected men in the trial from HIV infection.

Follow eMaxHealth on YouTube, Twitter and Facebook.
Please, click to subscribe to our Youtube Channel to be notified about upcoming health and food tips.

IAVI recognizes the critical importance of interim data released today by the NIH suggesting circumcision may cut in half men's risk of contracting HIV/AIDS through heterosexual sex. The two studies enrolling 2,784 HIV-negative men in Kisumu, Kenya and 4,996 HIV-negative men in Rakai, Uganda, demonstrated a 48% (Uganda) and 53% (Kenya) reduction of HIV acquisition in circumcised men relative to uncircumcised men. These data support the findings of a 2005 study, the South Africa Orange Farm Intervention Trial, funded by the French Agence Nationale de Recherches sur le SIDA (ANRS), which demonstrated at least a 60% reduction in HIV infection among circumcised men.

"We are enormously encouraged by these results," stated CEO and President of IAVI, Dr. Seth Berkley. "Any method of prevention which could reduce new HIV infections